Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system
- PMID: 21790310
- PMCID: PMC3192055
- DOI: 10.1089/cbr.2010.0907
Beta androstenediol mitigates the damage of 1 GeV/n Fe ion particle radiation to the hematopoietic system
Abstract
Space exploration is associated with exposure to 1-3 Gy solar particle radiation and galactic cosmic radiation that could increase cancer rates. Effective nontoxic countermeasures to high linear energy transfer (LET) radiation exposure are highly desirable but currently not available. The aim was to determine whether a single subcutaneous injection of androstenediol (Δ(5) androsten-3β, 17β-diol [AED]) could mitigate and restore the mouse hematopoetic system from the radiation-mediated injury of 3 Gy whole-body high LET (56)Fe(26+) exposure. The findings show that postradiation AED treatment has an overall positive and significant beneficial effect to restore the levels of hematopoeitic elements (p<0.001). Androstenediol treatment significantly increased monocyte levels at days 4, 7, and 14 and, similarly, increased red blood cell, hemoglobin, and platelet counts. Flow cytometry analysis 14 days after radiation and AED treatment demonstrated an increase (p<0.05) in bone marrow cells counts. Ex vivo osteoclastogenesis studies show that AED treatment is necessary and advantageous for the development and restoration of osteoclastogenesis after radiation exposure. These findings clearly show that androstenediol functions as a countermeasure to remedy hematopoeitic injury mediated by high LET iron ion radiation. Presently, no other agent has been shown to have such properties.
Figures
References
-
- Academies National Research Council. Vol. 1. Bethesda, Maryland USA: 2008. Managing Space Radiation Risk in the New Era of Space Exploration. Committee on the Evaluation of Radiation Shielding for Space Exploration, National Research Council, NCRP pub.
-
- National Council on Radiation Protection and Measurements (NCRP) Bethesda, Maryland USA: 1989. Guidance on Radiation Received in Space Activities. Report 98, NCRP pub.
-
- Cucinotta FA. Durante M. Cancer risk from exposure to galactic cosmic rays: Implications for space exploration by human beings. Lancet Oncol. 2006;7:431. - PubMed
-
- Boccia R. Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Semin Oncol. 2002;29:S9. - PubMed
-
- Dziegielewski J. Goetz W. Baulch JE. Heavy ions, radioprotectors and genomic instability: Implications for human space exploration. Radiat Environ Biophys. 2010;49:303. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
